Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
| OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
| SERIAL NUMBER |
88166503 |
| LAW OFFICE ASSIGNED |
LAW OFFICE 108 |
| MARK SECTION |
| MARK |
ZYREXAL (see, http://uspto.report/TM/88166503/mark.png) |
| STANDARD CHARACTERS |
YES |
| USPTO-GENERATED IMAGE |
YES |
| LITERAL ELEMENT |
ZYREXAL |
| OWNER SECTION (current) |
| NAME |
Vivera Pharmaceuticals, Inc. |
| MAILING ADDRESS |
4533 MacArthur Blvd., #5049 |
| CITY |
Newport Beach |
| STATE |
California |
| ZIP/POSTAL CODE |
92660 |
| STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
| OWNER SECTION (proposed) |
| NAME |
Vivera Pharmaceuticals, Inc. |
| MAILING ADDRESS |
4533 MacArthur Blvd., #5049 |
| CITY |
Newport Beach |
| STATE |
California |
| ZIP/POSTAL CODE |
92660 |
| STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
| EMAIL |
XXXX |
| CORRESPONDENCE INFORMATION (current) |
| NAME |
Stephen J. Straus |
| PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
ipdocket@buchalter.com |
| SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
sstrauss@buchalter.com; aharvey@buchalter.com |
| GOODS AND/OR SERVICES SECTION |
| INTERNATIONAL CLASS |
005 |
| CURRENT IDENTIFICATION |
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of
capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active
ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of prescription dosage capsules that facilitate the delivery of pharmaceutical preparations; Pharmaceutical
preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; all of the foregoing excluding pharmaceutical
preparations and substances for the treatment of the central nervous system, sleep disorders, and neurological diseases or disorders |
| GOODS OR SERVICES |
KEEP ALL LISTED |
| EXTENSION SECTION |
| EXTENSION NUMBER |
1 |
| ALLOWANCE MAIL DATE |
08/27/2019 |
| STATEMENT OF USE |
NO |
| PAYMENT SECTION |
| NUMBER OF CLASSES |
1 |
| SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
| TOTAL AMOUNT |
125 |
| SIGNATURE SECTION |
| ORIGINAL PDF FILE |
hw_381065369-191132090_._ 503_-_zyrexal.pdf |
CONVERTED PDF FILE(S)
(1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\881\665\88166503\xml1\ ESU0002.JPG |
| SIGNATORY'S NAME |
Olivia Karpinski |
| SIGNATORY'S POSITION |
Director |
| FILING INFORMATION |
| SUBMIT DATE |
Thu Feb 27 19:14:31 ET 2020 |
| TEAS STAMP |
USPTO/ESU-XX.XXX.XX.XX-20
200227191431026735-881665
03-710cdb52d868c7a7ad33d5
abbc2c8573fada754ec24dbd3
94cef35a212a261164-DA-143
04076-2020022719113209085
4 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
| OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: ZYREXAL (see, http://uspto.report/TM/88166503/mark.png)
SERIAL NUMBER: 88166503
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Vivera Pharmaceuticals, Inc., having an address of
4533 MacArthur Blvd., #5049
Newport Beach, California 92660
United States
Proposed: Vivera Pharmaceuticals, Inc., having an address of
4533 MacArthur Blvd., #5049
Newport Beach, California 92660
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 08/27/2019.
For International Class 005:
Current identification: Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled
release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of
pharmaceuticals; Drug delivery agents in the form of prescription dosage capsules that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, namely, a drug delivery
system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; all of the foregoing excluding pharmaceutical preparations and substances for the
treatment of the central nervous system, sleep disorders, and neurological diseases or disorders
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the first extension request.
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
Original PDF file:
hw_381065369-191132090_._ 503_-_zyrexal.pdf
Converted PDF file(s) (1 page)
Signature File1
Signatory's Name: Olivia Karpinski
Signatory's Position: Director
RAM Sale Number: 88166503
RAM Accounting Date: 02/27/2020
Serial Number: 88166503
Internet Transmission Date: Thu Feb 27 19:14:31 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XX-20200227191431026
735-88166503-710cdb52d868c7a7ad33d5abbc2
c8573fada754ec24dbd394cef35a212a261164-D
A-14304076-20200227191132090854
